Calliditas Therapeutics Reports TRANSFORM Phase 2b Topline Data In Primary Biliary Cholangitis
Portfolio Pulse from Benzinga Newsdesk
Calliditas Therapeutics AB (NASDAQ:CALT) announced that its Phase 2b TRANSFORM trial for setanaxib in primary biliary cholangitis (PBC) met its primary endpoint, showing significant improvement in ALP levels.
July 26, 2024 | 6:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Calliditas Therapeutics' Phase 2b TRANSFORM trial for setanaxib in PBC met its primary endpoint, showing significant improvement in ALP levels. This positive result could boost investor confidence and potentially increase the stock price in the short term.
The successful Phase 2b trial results for setanaxib in PBC are a significant milestone for Calliditas Therapeutics. Meeting the primary endpoint with statistically significant improvement in ALP levels is likely to enhance investor confidence and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100